Sun 11/18/2018 05:03 ET
DJIA25413.22124.520.49%TELCO170.142.211.30%GOLD1222.0022.851.87%Shanghai2679.1110.980.41%
S&P 5002736.276.020.22%BANKS448.240.000.00%OIL56.830.370.65%BITCOIN5543.3342.680.77%
NASDAQ7247.8710.870.15%PHARM586.330.000.00%US/EU1.140.000.01%Futures2742.257.680.28%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Daxor Corp - DXR   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DXR
  
From: SunTzu772 (Rep: 1078) reply to SunTzu772Date: 11/09/2018 02:52
Forum: Daxor Corp - Msg #110Thread #674044798 (Rec: 0)
Re: 7.80 small CFO buy @ 7.42 major news 790k float - New Study Cites 82 Percent Mortality and 56 Percent => initial alert @ 5.34

----

https://www.sec.gov/Archives/edgar/data/27367/000149315218015451/xslF345X03/ownership.xml

----

http://www.thelion.com/bin/forum.cgi?sf=dxr&msg=107&cmd=r&t=

----





------------------- "Opportunities multiply as they are seized" -- Sun Tzu circa 500 B.C. -------------------



Reply to SunTzu772 - Msg #86 - 10/30/2018 10:50

5.34 major news 790k float - New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients

----

GlobeNewswire•October 30, 2018

----
Controlled Study of BVA-100 Published in The Journal of the American College of Cardiology – Heart Failure Showed 86 Percent Reduction in One-Year Mortality
----

NEW YORK , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of new data in the Journal of the American College of Cardiology – Heart Failure showing statistically significantly reduced 30-day readmission and 30-day and 1-year mortality rates in patients who received individualized treatment for acute heart failure guided by blood volume measurement with the BVA-100 blood volume analyzer, compared to propensity-matched controls.
----

“This is a landmark study for Daxor as it provides peer review validation in a leading cardiology journal of the value of our technology and its potential to improve heart failure outcomes. Heart failure represents one of the largest areas of healthcare spending and one of the most significant treatment challenges for approximately 6 million US patients, which is expected to double as the population ages,” commented Michael Feldschuh, CEO of Daxor. “The BVA-100 provides a simple, rapid, inexpensive, non-invasive, and most importantly, objective measurement of volume status and composition. This precision enables individualization of treatment and significantly better outcomes for patients.”
----

Treatment guided by the BVA-100 blood volume analyzer resulted in a statistically significant decrease in rehospitalization (12.2 percent vs. 27.7 percent, p<0.001), 30-day mortality (2.0 percent vs. 11.1 percent, p<0.001) and 365-day mortality (4.9 percent vs. 35.5. percent, p<0.001), compared to a propensity score control. Further, an analysis of 30-day readmission by diagnosis showed fewer heart failure readmissions (6.1 percent vs. 20.2 percent, p<0.001) and fewer cardiac non-heart failure admissions (1.6 percent vs. 3.9 percent, p<0.001).
----

"The results of this outcome study demonstrate without question that accurate blood volume measurement substantially improves the physician’s ability to prescribe decongestion therapy that will result in significantly better outcomes in acute heart failure, particularly with regard to rehospitalization and mortality,” said John E. Strobeck, M.D., Ph.D., Director, Heart-Lung Consultants, Inc., Hawthorne, NJ and lead author of the study. “These results clearly show that BVA measurement has a one-to-one relationship in achieving meaningful improvements in clinical and resource-use outcomes in patients hospitalized for acute heart failure.”

----
Total blood volume, red blood cell volume and plasma volume were measured using Daxor’s BVA-100, an I-131 labeled albumin indicator dilution technique that is unique to the BVA-100. Patients were assigned a decongestion and treatment strategy based on the BVA-100 measurement. Propensity score control matching was derived from CMS data matching 10:1 for demographics, comorbidity and year of treatment.

----
https://globenewswire.com/news-release/2018/10/30/1639097/0/en/New-Study-Cites-82-Percent-Mortality-and-56-Percent-Rehospitalization-Reductions-30-Days-After-Therapy-Guided-by-Daxor-s-BVA-100-Blood-Volume-Analyzer-in-Acute-Heart-Failure-Patien.html
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser SunTzu772: Reward | Watch | IgnoreDXR: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DXR
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.